Logo


Claris Lifesciences extends fall after board approves delisting proposal

The stock was down 3% to Rs 352, falling 6% from its early morning high of Rs 374 on the BSE.

Claris get nod for Tobramycin injection is the US

Claris Lifesciences was down 3% to Rs 352, falling 6% from its early morning high of Rs 374 on the BSE on Thursday, after the board of directors of the company approved the delisting proposal received from the promoter Athanas Enterprise Pvt Ltd. The stock ended 1% lower at Rs 362 on Wednesday. "The promoter/promoter group of the company has made a voluntarily delisting offer representing 49.87% of the paid-up share capital of the company held by public shareholders," Claris Lifesciences said in a BSE filing. During the board meeting held on December 6, 2017, the ...